Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07020819 · ClinicalTrials.gov registry record · Phase 3
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
A Phase 3 study of Guillain-Barre Syndrome, sponsored by Annexon.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT07020819 is a Phase 3 study of Guillain-Barre Syndrome that is actively recruiting participants, run by Annexon. The registered enrollment target is 30 participants. The trial reports 9 study locations across 8 states.
The verdict
NCT07020819, a Phase 3 study of Guillain-Barre Syndrome, is actively recruiting participants, sponsored by Annexon.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Conditions Studied
Interventions
- DRUG Tanruprubart
Study Locations (9)
California
- Children's Hospital of Orange County - Orange
- University of California Irvine - Orange
Arizona
- HonorHealth Bob Bové Neuroscience Institute - Scottsdale
Colorado
- University of Colorado Hospital - Aurora
Louisiana
- Ochsner LSU Health - Shreveport
Massachusetts
- University Massachusetts Chan Medical School - Worcester
Michigan
- Henry Ford Health - Detroit
Minnesota
- Mayo Rochester - Rochester
Aarhus N
- Aarhus University Hospital - Aarhus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-12 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07020819
The ClinicalTrials.gov registry entry for NCT07020819 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annexon, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Guillain-Barre Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Tanruprubart is the first listed.
NCT07020819 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT07020819 about?
NCT07020819 is a clinical study titled "An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)". The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
What is the current status of trial NCT07020819?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2025-09-12. Estimated completion is 2028-06-30.
What conditions does trial NCT07020819 study?
This clinical trial studies the following conditions: Guillain-Barre Syndrome.
What interventions are being tested in trial NCT07020819?
The interventions under investigation include: Tanruprubart (DRUG).
Who is sponsoring clinical trial NCT07020819?
This trial is sponsored by Annexon, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07020819 being conducted?
This trial has 9 study locations across Arizona, California, Colorado, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Guillain-Barre Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.